September 29, 2022
Maruishi Pharmaceutical has filed a new drug application in Japan for an injectable agent containing difelikefalin, MR13A9, for the treatment of pruritus in hemodialysis patients, the company and its codeveloper Kissei Pharmaceutical said on September 28. Difelikefalin, a selective kappa...read more